STAT3 and cancer: We therefore speculated that, similar to other pathway-targeted cancer drugs [61], cell lines in which the nintedanib-driven blockade of the FGFR/SRC/STAT3 axis fails to fully suppress STAT3 activity could activate the JAK/STAT3 axis as a compensatory mechanism, which might be responsive to silibinin (Figure 3).